We are live on ! Find out more
TMBR

Timber Pharmaceuticals, Inc.
TMBR

Delisted

TMBR was delisted on the 28th of November, 2023.

Back to rankings

16 hedge funds and large institutions have $752K invested in Timber Pharmaceuticals, Inc. in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

26% more capital invested

Capital invested by funds: $595K → $752K (+$157K)

23% more funds holding

Funds holding: 13 → 16 (+3)

Holders
16
Holders Change
+3
Holders Change %
+23.08%
% of All Funds
0.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
4
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$495K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$91.9K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$53.8K
4
Bank of New York Mellon
Bank of New York Mellon
New York
+$48.9K
5
TSS
Two Sigma Securities
New York
+$46.7K

Top Sellers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
-$6K
2
Renaissance Technologies
Renaissance Technologies
New York
-$5K
3
VF
Virtu Financial
New York
-$3K
4
UBS Group
UBS Group
Switzerland
-$772
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$495K +$495K +59,043 +252%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$94K +$91.9K +10,955 +229%
TSS
3
Two Sigma Securities
New York
$39K +$46.7K +5,567 +588%
Susquehanna International Group
4
Susquehanna International Group
Pennsylvania
$38K +$53.8K +6,409 New
Bank of New York Mellon
5
Bank of New York Mellon
New York
$35K +$48.9K +5,828 New
Northern Trust
6
Northern Trust
Illinois
$15K – – –
State Street
7
State Street
Massachusetts
$13K – – –
Barclays
8
Barclays
United Kingdom
$12K – – –
UBS Group
9
UBS Group
Switzerland
$5K -$772 -92 -9%
SG
10
StoneX Group
New York
$2.14K +$2.99K +356 New
Victory Capital Management
11
Victory Capital Management
Texas
$2K +$2.45K +292 New
TRCT
12
Tower Research Capital (TRC)
New York
$1K +$1.56K +186 New
MSFS
13
Main Street Financial Solutions
Pennsylvania
$1K +$1.84K +220 New
Citigroup
14
Citigroup
New York
– -$6K -400 Closed
Renaissance Technologies
15
Renaissance Technologies
New York
– -$5K -316 Closed
VF
16
Virtu Financial
New York
– -$3K -218 Closed
Wells Fargo
17
Wells Fargo
California
– +$84 +10 +125%

TMBR Hedge Fund Activity: Q3 2022 in Review

16 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Timber Pharmaceuticals, Inc. (TMBR) for Q3 2022, worth a combined $752K — up 26% from $595K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new TMBR positions and 3 closed out — a net gain of 3 holders — while 4 added to existing stakes and 1 trimmed.

The largest buyer was Vanguard Group, adding an estimated $495K. The largest seller was Citigroup, exiting entirely with an estimated $6K sold.

  • 16 institutional investors held Timber Pharmaceuticals, Inc. (TMBR) as of Q3 2022, up from 13 in Q2 2022.
  • Funds reported $752K of Timber Pharmaceuticals, Inc. stock for Q3 2022, up 26% quarter-over-quarter.
  • 6 funds opened new Timber Pharmaceuticals, Inc. positions in Q3 2022 and 3 closed out, a net change of +3 holders.
  • The largest Timber Pharmaceuticals, Inc. buyer in Q3 2022 was Vanguard Group, an estimated $495K added.
  • The largest Timber Pharmaceuticals, Inc. seller in Q3 2022 was Citigroup, an estimated $6K sold.

Based on aggregated 13F filings for Q3 2022.